EUROIMMUN Logo
Find
X

What are you looking for?

Filter for products in our complete portfolio

Product finder

Worldwide
X
EUROIMMUN worldwide

This website provides an overview of the business activities and products of EUROIMMUN AG worldwide. Not all products are registered and approved in all countries or regions. Please contact your country representative for product availability and information

EUROIMMUN branches

Choose your country

Europe

North America

South & Central America

Asia

Middle East & Africa

EUROIMMUN Logo
Product finder

Goodpasture's syndrome

Clinical information

Anti-GBM disease is a type of small vessel vasculitis. It is characterised by the presence of autoantibodies against the non-collagenous domain 1 of the α3-chain of type IV collagen (α3(IV)NC1). The target antigen is localised in the glomerular basement membrane of the kidney and in the basement membrane of the pulmonary alveoli. The majority of patients suffer from rapidly progressive glomerulonephritis with micro- or macrohaematuria, usually mild proteinuria and anuria. If the kidneys and lungs are affected (as in 60 to 80 % of patients), it is called Goodpasture's syndrome. In 20% to 40% of patients with anti-GBM disease, only the kidneys are affected, in a small proportion only the lungs. Untreated, anti-GBM disease can quickly lead to renal failure, lung failure and death. Its incidence is estimated at 0.5 to 1.6 cases per million per year. Anti-GBM autoantibodies are pathogenic:: high titers usually occur in patients with rapidly progressive kidney disease. If the antibodies are removed early by plasma exchange, the prognosis improves. Relapses are rare if anti-GBM autoantibodies are no longer produced after plasma exchange and under immunosuppression. If anti-GBM autoantibodies can be detected in the blood before a kidney transplant, a relapse in the transplanted kidney is very likely.

Diagnostics

The diagnosis of anti-GBM disease in patients with symptoms of glomerulonephritis with or without lung involvement is based on the detection of anti-GBM autoantibodies in serum or kidney tissue. The antibodies can be determined in the indirect immunofluorescence test (IIFT) using frozen sections of monkey kidney or in monospecific immunoassays with purified NC1 domain (e.g. ELISA, ChLIA, line blot, antigen dots in IIFT). Detection of the antibodies in a kidney tissue sample helps to confirm the diagnosis. Up to 35% of patients with anti-GBM disease have antibodies against the cytoplasm of neutrophil granulocytes (ANCA, mostly against myeloperoxidase (MPO)). Up to 10% of patients with ANCA have anti-GBM autoantibodies. In the case of a negative serological result and a continuing suspicion of anti-GBM glomerulonephritis, a kidney biopsy is advisable.

Files

Antibody detection in autoimmune nephropathies

Products

Filter techniques:

Method
Parameter
Substrate
Species
EUROLINE
myeloperoxidase (MPO)
proteinase 3 (PR3)
glomerular basement membrane (GBM)
EUROLINE
Details
ChLIA
IDS ANCA/GBM Control Set 1
3 x 1.5mL Control 1/2
Details
IIFT
renal glomeruli (GBM)
and renal tubuli
kidney
monkey
Details
IIFT
Nephrology Screen (KM) EUROPattern
renal glomeruli (GBM)


kidney

monkey
Details
IIFT
EUROPLUS
kidney glomeruli and tubuli
glomerular basement membrane (GBM)
2 BIOCHIPs per field:
kidney
GBM BIOCHIPs

monkey
Details
IIFT
EUROPLUS Nephrology Screen 1 EUROPattern
Renal glomeruli (GBM)
glomerular basement membrane (GBM)
2 BIOCHIPs per field
kidney
GBM-EUROPLUS

monkey

Details
ELISA
glomerular basement membrane
(GBM)
antigen-coated
microplate wells
Details
ChLIA
IDS GBM 1
antigenic coated magnetic particles
Details
ChLIA
Control set Anti-GBM ChLIA (IgG)
2 x 0.4 ml control 1/2
Details
ChLIA
Anti-GBM ChLIA (IgG)
Antigen-coated magnetic particles
Details
1Product manufactured by third party. Please contact your local EUROIMMUN representative for more information.
Show all products
Back to top
Contact person on site
Please click on a country or enter yours
North America
South & Central America
Europe
Asia
Oceania
Middle East & Africa